Sixty subjects ( New York Heart Association [ NYHA ] functional class II-III , left ventricular ejection fraction ( LVEF ) 40 % , left ventricular end-diastolic diameter 50 mm to < 80 mm ) receiving optimal pharmacologic therapy were randomized at 10 sites .